论文部分内容阅读
第一代溶栓药(链激酶、尿激酶)及alteplase和Saruplase等纤维蛋白特异性的溶栓药,长时间静脉内持续给药已被一次静脉推注、快速点滴、二种溶栓药联合静滴所代替。通过删除、置换或两分子杂交制备了许多简化的alteplase和Saruplase分子,但无溶栓作用。重组葡萄球菌激酶和纤维蛋白溶酶原激活剂具有令人感兴趣的特性。抗纤维蛋白片段或抗活化的血小板表位的单抗,是以血栓为靶的溶栓药物。溶栓治疗要联合应用抗栓药,以防再堵塞。正在进行临床观察比较水蛭素、全身性凝血酶抑制剂是否优于肝素,新的抗血小板药物,包括血小板受体单抗和裂解剂是否比阿司匹林更有效。
The first generation of thrombolytics (streptokinase, urokinase) and fibrin-specific thrombolytic agents such as alteplase and Saruplase have been administered intravenously once for a long time by intravenous bolus, bolus, and two thrombolytic agents Intravenous infusion instead. Many simplified alteplase and Saruplase molecules were prepared by deletion, substitution or two-way hybridization without thrombolysis. Recombinant staphylokinase and plasminogen activator have interesting properties. Antibodies to fibrin fragments or anti-activated platelet epitopes are thrombolytic agents targeted by thrombi. Thrombolytic therapy should be combined with antithrombotic drugs to prevent further plugging. Clinical trials are underway to compare whether hirudin, systemic thrombin inhibitors are superior to heparin, whether new antiplatelet drugs, including platelet receptor monoclonal antibodies and lysates, are more effective than aspirin.